Association of cytogenetics and immunophenotype in prognosis of children with acute lymphoblastic leukemia: Literature Review

  • سال انتشار: 1393
  • محل انتشار: مجله پزشکی بالینی، دوره: 1، شماره: 1
  • کد COI اختصاصی: JR_RCM-1-1_001
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 323
دانلود فایل این مقاله

نویسندگان

Abdollah Banihashem

Department of Pediatrics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Ali Ghasemi

Department of Pediatrics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Lueisa Tavasolian

Department of Pediatrics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

چکیده

Acute lymphoblastic leukemia (ALL) is the most common type of neoplastic disorder diagnosed in childhood. It is the cause of one third of all pediatric malignancies. ALL is characterized by the abnormal production and proliferation of immature lymphoblasts in bone marrow (BM). It seems that ALL occurs due to a genetic mutation in DNA structure producing white blood cell (WBC) stem cells. Because ALL is a systemic disease, its primary management is based on chemotherapy.There are important risk factors responsible for the poor prognosis of  ALL in children less than 1 year old and greater than 10 years old, such as: high WBC, mature T cell ,mature B cell, central nervous system (CNS) involvement, DNA index < 1 (hypodiploid), triploidy, tetraploidy, Mixed-Lineage Leukemia (MLL) gene re-arrangement on 11q23, the Philadelphia chromosome t(9;22),  reduction in platelet count, hemoglobin> 10 at diagnosis, no remission at the end of induction therapy and Minimal residual disease at the end of consolidation therapy. Complications might appear during the treatment including tumor lysis syndrome, bleeding, renal failure, sepsis, seizure, thrombosis, etc. Some consequences might identify after a long-term follow-up such as learning impairment, growth retardation, and secondary malignancies. It is estimated that up to 90% of pediatric ALL cases are curable.

کلیدواژه ها

acute lymphoblastic leukemia, Cytogenetic, Immunophenotype, Prognosis

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.